Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
SE O'sullivan - British journal of pharmacology, 2007 - Wiley Online Library
Cannabinoids act at two classical cannabinoid receptors (CB 1 and CB 2 ), a 7TM orphan
receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 …
receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 …
An update on PPAR activation by cannabinoids
SE O'Sullivan - British journal of pharmacology, 2016 - Wiley Online Library
Some cannabinoids activate the different isoforms of PPARs (α, β and γ), as shown through
the use of reporter gene assays, binding studies, selective antagonists and knockout studies. …
the use of reporter gene assays, binding studies, selective antagonists and knockout studies. …
[HTML][HTML] A systematic review on the pharmacokinetics of cannabidiol in humans
…, NL Stone, AS Yates, SE O'Sullivan - Frontiers in …, 2018 - frontiersin.org
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions,
usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in …
usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in …
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease
SE O'Sullivan, DA Kendall - Immunobiology, 2010 - Elsevier
… Author links open overlay panel SE O'Sullivan a , DA Kendall b … OEA has anti-inflammatory
effects as demonstrated by reductions in 12-O-tetradecanoylphorbol-13-acetate-induced …
effects as demonstrated by reductions in 12-O-tetradecanoylphorbol-13-acetate-induced …
[HTML][HTML] Towards better delivery of cannabidiol (CBD)
SA Millar, RF Maguire, AS Yates, SE O'Sullivan - Pharmaceuticals, 2020 - mdpi.com
… Likewise, increases in the CBD metabolite, 7-OH-CBD, are also seen when these drugs are
co-… SEO, SAM and ASY are independent consultants and work as paid scientific advisors to …
co-… SEO, SAM and ASY are independent consultants and work as paid scientific advisors to …
A systematic review of cannabidiol dosing in clinical populations
…, AS Yates, TJ England, SE O'Sullivan - British journal of …, 2019 - Wiley Online Library
Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application
in a wide‐variety of contexts; however, its effective dose in different disease states remains …
in a wide‐variety of contexts; however, its effective dose in different disease states remains …
Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo …
OBJECTIVE Cannabidiol (CBD) and Δ 9 -tetrahydrocannabivarin (THCV) are nonpsychoactive
phytocannabinoids affecting lipid and glucose metabolism in animal models. This study …
phytocannabinoids affecting lipid and glucose metabolism in animal models. This study …
Time-dependent vascular actions of cannabidiol in the rat aorta
SE O'Sullivan, Y Sun, AJ Bennett, MD Randall… - European journal of …, 2009 - Elsevier
We have shown that the major active agent of Cannabis sativa, Δ 9 -tetrahydrocannabinol,
activates peroxisome proliferator-activated receptor gamma [PPARγ, O'Sullivan, SE, Tarling, …
activates peroxisome proliferator-activated receptor gamma [PPARγ, O'Sullivan, SE, Tarling, …
[HTML][HTML] A novel transwell blood brain barrier model using primary human cells
NL Stone, TJ England, SE O'Sullivan - Frontiers in cellular …, 2019 - frontiersin.org
Structural alterations and breakdown of the blood brain barrier (BBB) is often a primary or
secondary consequence of disease, resulting in brain oedema and the transport of unwanted …
secondary consequence of disease, resulting in brain oedema and the transport of unwanted …
Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen‐glucose deprivation via PPARγ and 5‐HT1A receptors
…, TJ England, SE O'Sullivan - British journal of …, 2016 - Wiley Online Library
Background and Purpose In vivo and in vitro studies have demonstrated a protective effect
of cannabidiol (CBD) in reducing infarct size in stroke models and against epithelial barrier …
of cannabidiol (CBD) in reducing infarct size in stroke models and against epithelial barrier …